Keyphrases
Hematological Malignancies
100%
Metabolic Syndrome
100%
Insulin Resistance
57%
Type 1 Diabetes Mellitus (T1DM)
42%
Obesity Resistance
42%
Growth Factors
28%
Insulin-like
28%
Obesity
14%
ERK Pathway
14%
Cancer Patients
14%
In Cancer
14%
Diabetes
14%
Central Obesity
14%
Hypertension
14%
United States
14%
PI3K Inhibitor
14%
Druggability
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Inflammatory Cytokines
14%
Dysregulated
14%
Insulin
14%
Statins
14%
Multiple Pathways
14%
Mammalian Target of Rapamycin (mTOR)
14%
ERK MAPK
14%
Dyslipidemia
14%
Receptor Antagonist
14%
Cytokine Effects
14%
A1 Receptor
14%
Direct Therapy
14%
Cancer Targeting
14%
Resistant Phenotypes
14%
MTOR Inhibitor
14%
Cytokine Activation
14%
Chemoresistant
14%
Resistance Type
14%
Mitogenic Effect
14%
Everolimus
14%
Temsirolimus
14%
Lipid Signaling
14%
Oral Hypoglycemic Agents
14%
Idelalisib
14%
Hematologic Neoplasms
14%
Adipokine Cytokines
14%
Linsitinib
14%
Medicine and Dentistry
Metabolic Syndrome
100%
Hematologic Malignancy
100%
Insulin Resistance
57%
Diabetes Mellitus
28%
Malignant Neoplasm
28%
Diseases
14%
Prevalence
14%
Maturity Onset Diabetes of the Young
14%
Dyslipidemia
14%
Diabetes
14%
Impaired Glucose Tolerance
14%
Mammalian Target of Rapamycin Inhibitor
14%
Statin
14%
Adipocytokine
14%
Everolimus
14%
Sulfhemoglobinemia
14%
Somatomedin C
14%
Antidiabetic Agent
14%
Temsirolimus
14%
Mammalian Target of Rapamycin
14%
Somatomedin C Receptor
14%
Idelalisib
14%
Inflammatory Cytokine
14%
Linsitinib
14%
Mitogen-Activated Protein Kinase
14%
Pharmacology, Toxicology and Pharmaceutical Science
Hematologic Malignancy
100%
Metabolic Syndrome X
100%
Insulin Resistance
57%
Malignant Neoplasm
42%
Diabetes Mellitus
28%
Adipocytokine
14%
Cytokine
14%
Prevalence
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Hematologic Disease
14%
Somatomedin C Receptor
14%
Somatomedin C
14%
Mammalian Target of Rapamycin Inhibitor
14%
Antidiabetic Agent
14%
Everolimus
14%
Idelalisib
14%
Linsitinib
14%
Disease
14%
Impaired Glucose Tolerance
14%
Dyslipidemia
14%
Temsirolimus
14%
Non Insulin Dependent Diabetes Mellitus
14%